Intellia Therapeutics NTLA 深 沪
等待开盘 09-13 09:30:00 美东时间
11.4755
+0.056
+0.49%
华盛通- 最 高11.645
- 今 开11.38
- 成交量 219.45万股
- 最 低 11.17
- 昨 收 11.42
- 总市值 11.93亿
- 52周最高 21.94
- 市盈率 静 --
- 换手率 2.11%
- 52周最低 5.90
- 委 比 46.86%
- 总股本 1.04亿
- 历史最高 202.73
- 量 比 0.57
- 振 幅 4.16%
- 历史最低 5.90
- 每 手 1
- 风险率 3.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股机会日报 | 8月非农大幅低于预期！纳指期货短线拉涨约0.7%；特斯拉盘前涨近2%
8月非农大幅低于预期！纳指期货短线拉涨约0.7%；特斯拉盘前涨近2%，董事会为马斯克提出新“天价”薪酬方案；博通盘前涨超13%，业绩超预期叠加与OpenAI合作自研AI芯片>>
09-05 20:38
Figma(FIG.US)大跌20%后，“木头姐”抄底买入10万股
凯西·伍德旗下的投资管理公司Ark Invest趁 Figma 股价下跌之际购入了该股票，其股价已下跌约 20%。
09-05 19:54
Cathie Wood's Swoops In On Figma's 20% Plunge, Ark Invest Scoops Up Shares Worth $5.9 Million
Ark Invest, led by Cathie Wood, bought 108,238 shares of Figma Inc. (NYSE: FIG) as its stock dropped 20%. Other key trades include selling Roku and buying Intellia Therapeutics.
09-05 09:07
投资者正获利了结？ARK创新ETF(ARKK.US)遭大规模赎回 “木头姐”伍德仍在逢低买入更多股票
由“木头姐”伍德管理的ARK创新ETF今年以来表现亮眼，但近期资金流向显示投资者可能在获利了结
08-20 06:00
ARK Investment buys 560K shares of Intellia Therapeutics
Cathie Wood's ARK Investment has purchased 560,600 shares of biotech and gene editing company Intellia Therapeutics (NASDAQ:NTLA). The stock has a Seeking Alpha quant rating of Hold, with the facto...
08-19 17:23
Cathie Wood's 'Apocalypse Squad' Play? Ark Scoops Up $14.2 Million Worth Of Robinhood Stock
Ark Invest, led by Cathie Wood, made significant trades on Monday, acquiring shares of Robinhood and Deere & Co. Other key trades also took place.
08-19 09:41
Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews
In the latest quarter, 9 analysts provided ratings for Intellia Therapeutics (N...
08-12 02:00
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
08-11 09:43
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress
Intellia Therapeutics reports strong progress in clinical trials for CRISPR-based therapies, including ahead-of-schedule enrollment in the MAGNITUDE trial for ATTR-CM and MAGNITUDE-2 study for ATTRv-PN. Lonvo-z's Phase 3 HAELO study is预计 to complete randomization by Q3 2025, and additional data from Phase 1/2 studies are expected in H2 2025. The company ended Q2 2025 with $630.5 million in cash, supporting operations into H1 2027. Collaboration r...
08-07 11:30
